Understand the source comparison
Peptides for Gut After Antibiotics: Research Protocol Comparison
BPC-157 VEGF upregulation, mucosal repair, tight junction stabilization 250–500mcg daily Subcutaneous or oral 4–6 weeks Best evidence for direct mucosal healing. Targets barrier integrity at the cellular level KPV NF-κB inhibition, anti-inflammatory, immune mo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, mucosal repair, tight junction stabilization
- 250–500mcg daily
- Subcutaneous or oral
- 4–6 weeks
- Best evidence for direct mucosal healing. Targets barrier integrity at the cellular level
- KPV
- NF-κB inhibition, anti-inflammatory, immune modulation
- 500mcg daily
- Strongest anti-inflammatory profile. Reduces cytokine expression that slows repair
- Thymalin
- Thymic peptide, immune regulation, T-cell modulation
- 5–10mg weekly
- Intramuscular
- 4–8 weeks
- Immune-focused. Supports systemic recovery but less direct gut mucosal action than BPC-157
- LL-37 (Cathelicidin)
- Antimicrobial peptide, pathogen clearance, barrier support
- 200–400mcg daily
- Topical or intranasal (experimental for gut)
- 2–4 weeks
- Emerging evidence for microbiome modulation but limited gut-specific data